BAM
VVOS icon

Blueshift Asset Management’s Vivos Therapeutics VVOS Stock Holding History

Blueshift Asset Management’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-753
Closed -$76K – 1250
2021
Q3 		$76K Buy
+753
New +$79.1K ﹤0.01% 966

Other funds holding VVOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Blueshift Asset Management's VVOS Position: Q4 2021 in Review

Blueshift Asset Management sold out of Vivos Therapeutics (VVOS) in Q4 2021, closing a stake of 753 shares — an estimated $76K sold.

Blueshift Asset Management first reported a position in VVOS in Q3 2021 and held it in 1 quarter. The position peaked at $76K in Q3 2021. 29 funds tracked by Wall St. Rank hold VVOS as of Q4 2021.

  • Blueshift Asset Management reported no remaining Vivos Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Blueshift Asset Management sold 753 Vivos Therapeutics shares in Q4 2021, an estimated $76K.
  • Blueshift Asset Management first reported a position in Vivos Therapeutics in Q3 2021 and held it in 1 quarter.
  • Blueshift Asset Management's Vivos Therapeutics position peaked at $76K in Q3 2021.
  • 29 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q4 2021.

Based on Blueshift Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.